Prima Biomed Ltd., of Sydney, said it expects the first patient in a phase IIb study of its lead compound, IMP321 (LAG-3Ig fusion protein), will be dosed early next year. The AIPAC (Active Immunotherapy PAClitaxel) study is a multicenter, randomized, double-blind, placebo-controlled trial in hormone receptor-positive metastatic breast carcinoma patients.